Skip to content
Screener

Alkermes ALKS Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.34B-12.2%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$161.5M+77.2%
AbbVie logo
AbbVieABBV
$34.11B+9.4%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$21M+23.5%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$5.32M+211%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$28.44M-51.9%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.11B+85.1%
Enterprise value$9.18B+133%
P/E122.7×+110×
P/S4.9×+2.0×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemJune 30, 2026December 31, 2025
CONTINGENT CONSIDERATION136,304
LONG-TERM DEBT1,476,611
DEFERRED TAX LIABILITIES179,575
OTHER LONG-TERM LIABILITIES68,01861,008
Total liabilities2,584,575667,698
COMMITMENTS AND CONTINGENT LIABILITIES (Note 18)
SHAREHOLDERS’ EQUITY:
Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; and zero issued and outstanding at June 30, 2026 and December 31, 2025, respectively.

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's other non-current liabilities?
Alkermes (ALKS) reported other non-current liabilities of $68.02M in Q2 2026.
How has Alkermes's other non-current liabilities changed year-over-year?
Alkermes's other non-current liabilities increased by 21.4% year-over-year, from $56.05M to $68.02M.
What is the long-term trend for Alkermes's other non-current liabilities?
Over 5 years (2020 to 2025), Alkermes's other non-current liabilities has grown at a 10.8% compound annual growth rate (CAGR), from $36.51M to $61.01M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

Ask your AI about Alkermes's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude